ODDO BHF Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

ODDO BHF Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Buy	8,642 +603	+8%	+$89.5K	0.07%	150
2026 Q1	$1.06M	Buy	8,039 +419	+5%	+$55.6K	0.04%	184
2025 Q4	$1.08M	Buy	7,620 +2,000	+36%	+$290K	0.04%	189
2025 Q3	$789K	Buy	+5,620	New	+$761K	0.03%	305

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ODDO BHF Asset Management's NBIX Position: Q2 2026 in Review

ODDO BHF Asset Management increased its Neurocrine Biosciences (NBIX) stake by 7.5% in Q2 2026, buying an estimated $89.5K and bringing the position to 8,642 shares worth $1.46M. The position accounts for 0.07% of the portfolio, ranked #150.

ODDO BHF Asset Management first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

ODDO BHF Asset Management held 8,642 shares of Neurocrine Biosciences worth $1.46M as of Q2 2026.
ODDO BHF Asset Management bought 603 Neurocrine Biosciences shares in Q2 2026, an estimated $89.5K.
Neurocrine Biosciences made up 0.07% of ODDO BHF Asset Management's portfolio in Q2 2026, its #150 holding.
ODDO BHF Asset Management first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on ODDO BHF Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.